Aktis Oncology (AKTS)

• Market cap: $1.07B
• 1 day: 8.68%
• 5 days: -3.77%
• 1 month: -8.93%
• 3 months: -8.93%
• 6 months: -8.93%
• Year to date: -8.93%
• 1 year: -8.93%
• 5 years: -8.93%
• 10 years: -8.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.